SEC Filing | Lexicon Pharmaceuticals

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wittouck Amaury

(Last)

(First)

(Middle)

VALLEY PARK, 44, RUE DE LA VALLEE

(Street)

LUXEMBOURG

L-2661

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/11/2021

3. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	32,259,461	I	See Footnotes⁽¹⁾⁽²⁾⁽⁵⁾
Common Stock	3,516,214	I	See Footnotes⁽¹⁾⁽³⁾⁽⁵⁾
Common Stock	35,402,689	I	See Footnotes⁽¹⁾⁽⁴⁾⁽⁵⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

1. On January 11, 2021, the Reporting Person became the sole member of the board of Stichting Administratiekantoor Westend (the "Stichting"), and therefore, may be deemed to beneficially own the securities reported herein. The Reporting Person disclaims beneficial ownership over the securities reported herein, except to the extent of his pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, the Reporting Person states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

2. These securities are directly held by Artal International S.C.A.

3. These securities are directly held by Invus Public Equities, L.P.

4. These securities are directly held by Invus, L.P.

5. The Reporting Person is the sole member of the board of the Stichting. The Stichting is the majority stockholder of Westend S.A. Westend S.A. is the parent company of Artal Group S.A. Artal Group S.A. is the sole stockholder of Artal International Management S.A., which is the managing partner of Artal International S.C.A. Artal International S.C.A. is the managing member of Invus Advisors, L.L.C. and through its Geneva branch is the sole stockholder of Artal Treasury Limited. Artal Treasury Limited is the managing member of Invus Public Equities Advisors, LLC. Invus Public Equities Advisors, LLC is the general partner of Invus Public Equities, L.P., and Invus Advisors, L.L.C. is the general partner of Invus, L.P.

Remarks:

Invus Partners, LLC directly holds 4,321,214 shares of Issuer common stock. Neither the Reporting Person nor any of the other entities listed in Footnote 5 hereof have any beneficial or pecuniary interest for purposes of Section 16 of the Exchange Act in the shares of Issuer common stock directly held by Invus Partners, LLC. For purposes of Section 16 of the Exchange Act, the Reporting Person and the other entities listed in Footnote 5 may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.

	/s/ Amaury Wittouk	01/21/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.